Welch & Forbes LLC Cuts Holdings in Johnson & Johnson $JNJ

Welch & Forbes LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 1.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 675,855 shares of the company’s stock after selling 11,287 shares during the quarter. Johnson & Johnson accounts for about 1.5% of Welch & Forbes LLC’s investment portfolio, making the stock its 14th biggest holding. Welch & Forbes LLC’s holdings in Johnson & Johnson were worth $125,317,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Winnow Wealth LLC raised its position in Johnson & Johnson by 374.4% in the 3rd quarter. Winnow Wealth LLC now owns 9,174 shares of the company’s stock worth $1,706,000 after buying an additional 7,240 shares during the last quarter. Hoge Financial Services LLC grew its stake in shares of Johnson & Johnson by 11.2% in the third quarter. Hoge Financial Services LLC now owns 1,536 shares of the company’s stock worth $285,000 after acquiring an additional 155 shares during the period. Cornerstone Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 1.6% during the third quarter. Cornerstone Wealth Management LLC now owns 56,104 shares of the company’s stock valued at $10,403,000 after purchasing an additional 898 shares during the last quarter. AlphaQuest LLC boosted its holdings in Johnson & Johnson by 139.3% in the third quarter. AlphaQuest LLC now owns 26,874 shares of the company’s stock worth $4,983,000 after purchasing an additional 15,645 shares during the last quarter. Finally, Argent Advisors Inc. grew its position in Johnson & Johnson by 5.7% in the 3rd quarter. Argent Advisors Inc. now owns 20,367 shares of the company’s stock worth $3,776,000 after purchasing an additional 1,100 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $227.10 on Friday. The company has a market capitalization of $547.16 billion, a P/E ratio of 20.55, a P/E/G ratio of 2.21 and a beta of 0.34. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $230.00. The firm’s 50 day simple moving average is $210.72 and its two-hundred day simple moving average is $191.57. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting the consensus estimate of $2.46. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The firm had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. During the same period last year, the firm earned $2.04 EPS. The company’s revenue was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s payout ratio is presently 47.06%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on JNJ. Guggenheim increased their price target on Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a report on Friday, January 23rd. Sanford C. Bernstein increased their target price on Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a report on Friday, January 23rd. Daiwa Capital Markets boosted their price target on Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a research note on Thursday. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday. Finally, Wolfe Research boosted their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $233.05.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: CHMP (European regulator) issued a positive opinion for AKEEGA (niraparib + abiraterone) for BRCA1/2-mutant metastatic hormone-sensitive prostate cancer — regulatory progress supports a new oncology revenue stream and raises upside to J&J’s pharma growth outlook. Read More.
• Positive Sentiment: Daiwa Capital Markets raised its JNJ price target to $237 and kept an Outperform rating, signaling buy-side confidence in near-term upside. Read More.
• Positive Sentiment: Morgan Stanley upgraded J&J citing a stronger growth outlook; that upgrade (and related coverage noting fresh annual highs) helped lift sentiment earlier in the session. Read More.
• Positive Sentiment: Scotiabank raised its target to $265 after J&J’s solid quarterly results and reiterated Outperform — another signals of analyst bullishness post-Q4. Read More.
• Neutral Sentiment: Wall Street coverage is broadly positive but measured — several outlets summarized consensus analyst targets and noted JNJ’s strong 12‑month performance; analysts remain cautiously optimistic rather than uniformly exuberant. Read More.
• Neutral Sentiment: Unusually high options volume was reported, indicating elevated trader interest and potential short‑term volatility; this is activity-driven rather than a directional fundamental change. Read More.
• Positive Sentiment: A U.S. judge dismissed a fraud lawsuit over J&J’s talc bankruptcy strategy, removing one near-term legal overhang — a favorable court outcome for liability risk. Read More.
• Negative Sentiment: Analysts and legal commentators warn the talc saga isn’t fully settled — a Seeking Alpha piece cautions that dismissal of a fraud claim doesn’t end broader talc litigation, keeping potential legal risk on the radar. Read More.
• Negative Sentiment: Insider selling: reports show the CEO sold roughly $22M in shares after Q4 results — raises governance/perception questions for some investors despite company explanations. Read More.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.